The Ethical Allocation of Remdesivir Within Hospitals
| dc.contributor.author | Comer, Amber R. | |
| dc.contributor.department | Health Sciences, School of Health and Human Sciences | en_US |
| dc.date.accessioned | 2023-06-16T20:45:24Z | |
| dc.date.available | 2023-06-16T20:45:24Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Recent evidence has shown that remdesivir may shorten length of hospital stay and recovery in COVID-19 patients. Many hospitals are experiencing shortages of remdesivir and are being forced to determine systems for the ethical allocation of this drug. Ethical allocation of remdesivir is imperative for upholding principles of justice during public health crisis.2 Currently, there is no consensus on the ethical distribution of remdesivir to patients within hospitals. This article discusses places of consensus, variance, and limitations of hospital level remdesivir allocation policies throughout the US during the COVID-19 pandemic. | en_US |
| dc.eprint.version | Author's manuscript | en_US |
| dc.identifier.citation | Comer, A. R. (2021). The Ethical Allocation of Remdesivir Within Hospitals. The Journal of Hospital Ethics, 7(2), 82–84. | en_US |
| dc.identifier.uri | https://hdl.handle.net/1805/33830 | |
| dc.language.iso | en_US | en_US |
| dc.relation.journal | The Journal of Hospital Ethics | en_US |
| dc.rights | Publisher Policy | en_US |
| dc.source | Author | en_US |
| dc.subject | ethical guiding principles | en_US |
| dc.subject | drug eligibility | en_US |
| dc.subject | remdesivir | en_US |
| dc.subject | COVID-19 | en_US |
| dc.title | The Ethical Allocation of Remdesivir Within Hospitals | en_US |
| dc.type | Article | en_US |